Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis.

DiSano KD, Royce DB, Gilli F, Pachner AR.

Front Immunol. 2019 Aug 2;10:1821. doi: 10.3389/fimmu.2019.01821. eCollection 2019.

2.

Differential neuro-immune patterns in two clinically relevant murine models of multiple sclerosis.

DiSano KD, Linzey MR, Royce DB, Pachner AR, Gilli F.

J Neuroinflammation. 2019 May 22;16(1):109. doi: 10.1186/s12974-019-1501-9.

3.

Clinical utility of a molecular signature in inflammatory demyelinating disease.

Pachner AR, DiSano K, Royce DB, Gilli F.

Neurol Neuroimmunol Neuroinflamm. 2018 Nov 9;6(1):e520. doi: 10.1212/NXI.0000000000000520. eCollection 2019 Jan.

4.

Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.

Gilli F, De La Torre AL, Royce DB, Pachner AR.

Int Immunopharmacol. 2018 Sep;62:1-6. doi: 10.1016/j.intimp.2018.06.030. Epub 2018 Jun 27.

PMID:
29960044
5.

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.

Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S.

Theranostics. 2017 Sep 26;7(17):4340-4349. doi: 10.7150/thno.18563. eCollection 2017.

6.

Pegylated interferon beta in the treatment of the Theiler's murine encephalomyelitis virus mouse model of multiple sclerosis.

Gilli F, Royce DB, DiSano KD, Pachner AR.

J Neuroimmunol. 2017 Dec 15;313:34-40. doi: 10.1016/j.jneuroim.2017.10.004. Epub 2017 Oct 9.

PMID:
29153606
7.

Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.

Gilli F, Li L, Royce DB, DiSano KD, Pachner AR.

J Neurovirol. 2017 Dec;23(6):825-838. doi: 10.1007/s13365-017-0570-8. Epub 2017 Sep 14.

PMID:
28913765
8.

Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.

Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT.

Cancer Lett. 2017 May 28;394:76-87. doi: 10.1016/j.canlet.2017.02.021. Epub 2017 Feb 27.

PMID:
28254412
9.

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis.

Gilli F, Royce DB, Pachner AR.

J Vis Exp. 2016 Nov 14;(117). doi: 10.3791/54616.

10.

The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice.

Cao M, Royce DB, Risingsong R, Williams CR, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2016 Jan;9(1):105-14. doi: 10.1158/1940-6207.CAPR-15-0325. Epub 2015 Nov 10.

11.

Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention.

Cao M, Onyango EO, Williams CR, Royce DB, Gribble GW, Sporn MB, Liby KT.

Pharmacol Res. 2015 Oct;100:135-47. doi: 10.1016/j.phrs.2015.07.024. Epub 2015 Jul 31.

PMID:
26238177
12.

Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.

To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT.

Carcinogenesis. 2015 Jul;36(7):769-81. doi: 10.1093/carcin/bgv061. Epub 2015 May 4.

13.

Genes, the environment and personalized medicine: We need to harness both environmental and genetic data to maximize personal and population health.

Carlsten C, Brauer M, Brinkman F, Brook J, Daley D, McNagny K, Pui M, Royce D, Takaro T, Denburg J.

EMBO Rep. 2014 Jul;15(7):736-9. doi: 10.15252/embr.201438480. Epub 2014 Jun 6. No abstract available.

14.

The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT.

Cancer Prev Res (Phila). 2014 Jul;7(7):698-707. doi: 10.1158/1940-6207.CAPR-14-0047. Epub 2014 May 9.

15.

The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.

Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT.

Carcinogenesis. 2013 Jan;34(1):199-210. doi: 10.1093/carcin/bgs319. Epub 2012 Oct 6.

16.

The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice.

Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K.

Cancer Prev Res (Phila). 2012 May;5(5):726-34. doi: 10.1158/1940-6207.CAPR-11-0404. Epub 2012 Mar 8.

17.

CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.

Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, Liby KT.

Cancer Prev Res (Phila). 2012 Jan;5(1):89-97. doi: 10.1158/1940-6207.CAPR-11-0359. Epub 2011 Sep 20.

18.

Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.

Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB.

Cancer Prev Res (Phila). 2010 Nov;3(11):1427-34. doi: 10.1158/1940-6207.CAPR-10-0197. Epub 2010 Oct 19.

19.

Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice.

Liby K, Risingsong R, Royce DB, Williams CR, Ma T, Yore MM, Sporn MB.

Cancer Prev Res (Phila). 2009 Dec;2(12):1050-8. doi: 10.1158/1940-6207.CAPR-09-0085. Epub 2009 Dec 1.

20.

Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN.

Pitha-Rowe I, Liby K, Royce D, Sporn M.

Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5339-47. doi: 10.1167/iovs.09-3648. Epub 2009 Jun 3.

PMID:
19494206
21.

Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT, Williams C, Royce D, Risingsong R, Musiek ES, Morrow JD, Sporn M, Beal MF.

PLoS One. 2009 Jun 1;4(6):e5757. doi: 10.1371/journal.pone.0005757.

22.

A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin.

Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Yoshizawa H, Gribble GW, Williams CR, Risingsong R, Royce DB, Dinkova-Kostova AT, Stephenson KK, Egner PA, Yates MS, Groopman JD, Kensler TW, Sporn MB.

Cancer Res. 2008 Aug 15;68(16):6727-33. doi: 10.1158/0008-5472.CAN-08-1123.

23.

Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.

Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB.

Clin Cancer Res. 2008 Jul 15;14(14):4556-63. doi: 10.1158/1078-0432.CCR-08-0040.

24.

The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.

Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E, Sporn MB.

Mol Cancer Ther. 2008 May;7(5):1251-7. doi: 10.1158/1535-7163.MCT-08-0023.

25.

A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland.

Liby K, Royce DB, Risingsong R, Williams CR, Wood MD, Chandraratna RA, Sporn MB.

Clin Cancer Res. 2007 Oct 15;13(20):6237-43.

26.

Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities.

Liby K, Honda T, Williams CR, Risingsong R, Royce DB, Suh N, Dinkova-Kostova AT, Stephenson KK, Talalay P, Sundararajan C, Gribble GW, Sporn MB.

Mol Cancer Ther. 2007 Jul;6(7):2113-9.

27.

The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.

Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB.

Cancer Res. 2007 Mar 15;67(6):2414-9.

28.

The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.

Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB.

Clin Cancer Res. 2006 Oct 1;12(19):5902-9.

29.

Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A.

Honda T, Liby KT, Su X, Sundararajan C, Honda Y, Suh N, Risingsong R, Williams CR, Royce DB, Sporn MB, Gribble GW.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6306-9. Epub 2006 Sep 25.

30.

The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.

Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4288-93.

31.

The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.

Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB.

Cancer Res. 2005 Jun 1;65(11):4789-98.

32.

The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.

Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, Berchuck A, Liby K, Risingsong R, Royce DB, Williams CR, Sporn MB.

Cancer Res. 2004 May 15;64(10):3566-71.

33.

Closer ties with HEALNet.

Royce D.

Hosp Q. 1999 Summer;2(4):6. No abstract available.

PMID:
10623075
34.

Asymmetric field calculations.

Prado KL, Royce DL.

Med Dosim. 1992;17(2):95-9.

PMID:
1616598
35.

Future issues for the census of Canada.

Pryor ET, Goldmann GJ, Royce DA.

Int Migr Rev. 1991 Spring;25(1):167-75.

PMID:
12316775
36.

Address register research for the 1991 census of Canada.

Royce D.

J Off Stat. 1986;2(4):447-55.

PMID:
12341363

Supplemental Content

Support Center